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doi:10.1Objective: Refractory bleeding after complex cardiovascular surgery often leads to increased length of stay,
cost, morbidity, and mortality. Recombinant activated factor VII administered in the intensive care unit can re-
duce bleeding, transfusion, and surgical re-exploration. We retrospectively compared factor VII administration
in the intensive care unit with reoperation for refractory bleeding after complex cardiovascular surgery.
Methods: From 1501 patients who underwent cardiovascular procedures between December 2003 and Septem-
ber 2007, 415 high-risk patients were identified. From this cohort, 24 patients were divided into 2 groups based
on whether they either received factor VII in the intensive care unit (n ¼ 12) or underwent reoperation (n ¼ 12)
for refractory bleeding. Preoperative and postoperative data were collected to compare efficacy, safety, and eco-
nomic outcomes.
Results: In-hospital survival for both groups was 100%. Factor VII was comparable with reoperation in achiev-
ing hemostasis, with both groups demonstrating decreases in chest tube output and need for blood products.
Freedom from reoperation was achieved in 75% of patients receiving factor VII, whereas reoperation was ef-
fective in achieving hemostasis alone in 83.3% of patients. Prothrombin time, international normalized ratio,
and median operating room time were significantly less (P< .05) in patients who received factor VII. Both
groups had no statistically significant differences in other efficacy, safety, or economic outcomes.
Conclusions: Factor VII administration in the intensive care unit appears comparable with reoperation for
refractory bleeding after complex cardiovascular surgical procedures and might represent an alternative to re-
operation in selected patients. Future prospective, randomized controlled trials might further define its role.
(J Thorac Cardiovasc Surg 2011;141:1469-77)P
MSupplemental material is available online.
Refractory bleeding is a potentially serious complication of
complex cardiovascular surgery.1-7 Topical hemostatic
agents, transfusion of red cells and clotting factors, and
re-exploration are used when appropriate.1-7 Bleeding,
massive transfusion, and re-exploration increase hospital
length of stay (LOS), overall cost, morbidity, and mortal-
ity.1,7 When standard hemostatic interventions fail,
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The Journal of Thoracic and CarRecombinant activated factor VII (rFVIIa; NovoSeven;
Novo Nordisk, Princeton, NJ) is approved by the US Food
and Drug Administration for the treatment of bleeding in
patients with hemophilia A or B with inhibitors to factor
VIII or IX, respectively, for surgical procedures in this pa-
tient population and in patients with congenital factor VII
deficiency and Glanzmann’s thromboasthenia.8 Off-label
use of rFVIIa has expanded to other postsurgical popula-
tions, including cardiovascular surgery for the control of
hemorrhage.9-19 In addition, rFVIIa administration in the
intensive care unit (ICU) after cardiovascular procedures
reduces bleeding and transfusion requirements and might
avoid re-exploration.9,10,12,14-16,18,19 However, concerns
over the safety and cost of rFVIIa have created
controversy about its use in this patient population.8,19,20
The purpose of this study is to evaluate the clinical and
economic outcomes of initial rFVIIa administration in the
ICU after complex cardiovascular surgery compared with
reoperation to treat refractory postoperative bleeding.
MATERIALS AND METHODS
Patient Population
A retrospective chart review was conducted of all adult cardiovascular
surgery patients 18 years of age or older at the Medical University of Southdiovascular Surgery c Volume 141, Number 6 1469
Abbreviations and Acronyms
ICU ¼ intensive care unit
LOS ¼ length of stay
MUSC ¼ Medical University of South Carolina
OR ¼ operating room
PRBC ¼ packed red blood cell
rFVIIa ¼ recombinant activated factor VII
TF ¼ tissue factor
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MCarolina (MUSC) between December 2003 and September 2007. A high-
risk subset was defined as patients undergoing cardiac transplantation,
aortic surgery, redo operations, or combined multiple cardiac procedures.
Patients requiring thoracoabdominal aortic procedures, use of a ventricular
assist device or extracorporeal membrane oxygenation, surgical correction
for congenital heart disease, cardiovascular procedures in the setting of
multiple trauma, resection of cardiac tumors, and pericardiectomy and pa-
tients who died in the operating room (OR) were excluded. Patients who
received rFVIIa in the OR during the primary procedure were also ex-
cluded. From this high-risk subset, patients were further excluded if they
received antifibrinolytics other than aprotinin or anticoagulants other
than heparin. This study was approved by our institutional review board,
and individual patient consent was waived.
The remaining patients in this high-risk subset were screened for post-
operative bleeding, which was defined as a chest tube output of 3 mL $
kg1 $ h1 or greater for 2 or more consecutive hours and/or requirement
for re-exploration for bleeding, cardiac tamponade, or hemothorax within
the first 24 hours after the primary operation. Patients meeting the above
criteria for bleeding were then evaluated for use of rFVIIa in the ICU or
reoperation. All patients who received rFVIIa in the ICU or underwent re-
operation for bleedingwithin the first 24 hours were enclosed in this cohort.
Patients’ demographics, preoperative risk factors, rFVIIa dosing character-
istics, blood product use, coagulation laboratory values, operative charac-
teristics, the need for reoperation for bleeding after the primary procedure,
chest tube output, in-hospital outcomes, and hospital economic data were
recorded. Available data were collected through the Division of Cardiotho-
racic Surgery’s Society of Thoracic Surgeons Adult Cardiac Surgery data-
base. The European System for Cardiac Operative Risk Evaluation
(EuroSCORE) score system was used to evaluate the severity risk for
each group.Threshold for Reoperation or rFVIIa Use
Before 2006, rFVIIa was not used in the ICU after cardiovascular sur-
gery at MUSC. Reoperation was the primarymodality in treating refractory
postoperative bleeding. The decision for reoperation was made by the sur-
gical team after considering the following criteria: (1) chest tube output of
3 mL $ kg1 $ h1 or greater for 2 or more consecutive hours; (2) reversal of
coagulopathy, as evidenced by normalization of coagulation laboratory
values (international normalized ratio, 1.5; platelet count, 100,000/
mm3; and fibrinogen level,>200 mg/dL); (3) correction of the patient’s
core body temperature to 35C or greater; and (4) adequate heparin reversal
with protamine defined as an activated partial thromboplastin time of 1.5
times or less than our laboratory control (45 seconds). Patients were also
considered candidates for reoperation if there was concern for surgical
sources of bleeding, evidence of cardiac tamponade, mediastinal hema-
toma, or large hemothorax.
In 2006, we began using rFVIIa as an alternative to reoperation in post-
operative patients with refractory bleeding after cardiovascular surgery.
The decision to administer rFVIIa was made by the surgical team after
considering the same criteria as above, provided there was a low index1470 The Journal of Thoracic and Cardiovascular Surof suspicion for a surgical cause of bleeding and no evidence of cardiac
tamponade, mediastinal hematoma, or hemothorax.
End Points
The primary end points of this study were efficacy, adverse events, and
cost. Efficacy was determined by means of (1) evaluation of chest tube out-
put and avoidance of reoperation, (2) blood product use before and after in-
tervention, and (3) outcome measures, including OR time, ventilator time,
ICU and hospital LOS, and survival. Adverse events were compared be-
tween the groups with regard to complications including pneumonia, me-
diastinitis, thrombosis and thromboembolism, renal failure defined as an
increase in serum creatinine level to greater than 2 mg/dL or 2 times the
most recent preoperative level or a new requirement for dialysis, and death.
Cost was compared by using hospital cost, charges, reimbursement, and
profit. To account for time-related inflationary changes, cost information
was normalized to 2009 by using the US Bureau of Labor Statistics Con-
sumer Price Index. Additionally, hospital costs were also adjusted for
increases in hospital capital expenditures over time.
Statistical Analysis
Continuous variables are reported as medians with ranges caused by
data nonparametricity. Categorical variables are reported as counts with
percentages. Preintervention and postintervention chest tube outputs
were examined with the Wilcoxon matched-pairs signed-rank test. Demo-
graphics, risk factors, operative characteristics, outcome parameters, and
financial data were compared between the rFVIIa and reoperation groups
by using the Fisher exact test for categorical variables and the Mann-
Whitney test for continuous variables.
RESULTS
Demographic and Procedural Data
Between December 2003 and September 2007, 1501 pa-
tients underwent cardiovascular procedures at MUSC. After
exclusions, 421 cases performed in 415 high-risk patients
were identified and subsequently screened for postoperative
bleeding. In this cohort 25 patients were found to meet the
postoperative bleeding criteria. This resulted in a calculated
incidence of excessive postoperative bleeding of 5.9% (25/
421). Twelve patients received rFVIIa in the ICU after their
primary operation as the primarymode of therapy for refrac-
tory coagulopathy, and 12 patients underwent reoperation
for bleeding without receiving rFVIIa in the ICU. One
patient underwent neither intervention and was included
to determine the incidence of postoperative bleeding.
There were no statistically significant differences in pa-
tients’ demographics, history of thromboembolism, coagul-
opathy, previous cardiac surgery, anticoagulant use, or
preoperative risk factors for bleeding between the groups.
The additive EuroSCORE was not significantly different
between groups and demonstrated a high-risk severity at
baseline (Table 1).
Types of operations were similar between groups. Circu-
latory arrest time was significantly longer in the reoperation
group (18 vs 10 minutes, P¼ .01), but otherwise, there were
no differences in operative characteristics. Intraoperative
use of additional pharmacologic agents was infrequent
and similar between groups. Additional pharmacologic
agents to control bleeding in the ICUwere used in 8 patientsgery c June 2011
TABLE 1. Comparison of patients’ demographics and risk factors for
bleeding and thrombosis in patients receiving rFVIIa or reoperation
for refractory coagulopathy in the intensive care unit
Demographics/risk factor
rFVIIa
(n ¼ 12)
Reoperation
(n ¼ 12)
P
value
Age (y)
Median 64 61 .671
Range 24–78 18–81
EuroSCORE (additive)
Median 7.5 9.0 .178
Range 3–13 5–19
Sex (female) 1 (8%) 4 (33%) .317
Race
White 11 (92%) 10 (83%) 1.000
African American 1 (8%) 2 (17%)
History of coagulopathy 0 0
Renal insufficiency 1 (8%) 3 (25%) .590
Peripheral vascular disease 1 (8%) 0 (0%) 1.000
Previous MI 0 (0%) 2 (17%) .478
Previous CVA 1 (8%) 0 (0%) 1.000
Emergency status 2 (17%) 2 (17%) 1.000
Redo operations 3 (25%) 3 (25%) 1.000
Preoperative anticoagulants 7 (58%) 6 (50%) 1.000
Aspirin 4 (33%) 6 (50%) .680
Coumadin 1 (8%) 0 (0%) 1.000
Heparin/LMWH 0 (0%) 2 (27%) .478
Clopidogrel 1 (8%) 0 (0%) 1.000
Other 3 (25%) 0 (0%) .217
Multiple agents 2 (17%) 2 (17%) 1.000
Insurance status
Government 8 (67%) 6 (50%) .426
Private 3 (25%) 5 (42%)
Other 0 (0%) 1 (8%)
Uninsured 1 (8%) 0 (0%)
rFVIIa, Recombinant activated factor VII; MI, myocardial infarction; CVA, cerebro-
vascular accident; LMWH, low-molecular-weight heparin.
TABLE 2. Primary operative characteristics in patients who received
rFVIIa or reoperation for refractory coagulopathy in the intensive
care unit
Characteristics
rFVIIa
(n ¼ 12)
Reoperation
(n ¼ 12)
P
value
Type of operation, n (%)
Aorta surgery 6 (50%) 7 (58%) .815
Multiple procedures 3 (25%) 2 (17%)
Cardiac transplantation 2 (17%) 1 (8%)
Redo 1 (8%) 2 (17%)
CPB (min)
Median 189 168 .551
Range 109–275 105–248
Crossclamp (min)
Median 108 109 .928
Range 74–191 69–162
Circulatory arrest (min)
Median 10 18 .010
Range 6–16 14–24
Additional agents given to
control bleeding, n (%)
OR, primary operation 2 (17%) 3 (25%) 1.000
Intensive care unit 8 (67%) 5 (42%) .414
Protamine 8 (67%) 4 (33%) .220
DDAVP 0 (0%) 3 (25%) .217
Vitamin K 0 (0%) 1 (8%) 1.000
Multiple agents 0 (0%) 2 (17%) .478
rFVIIa, Recombinant activated factor VII; CPB, cardiopulmonary bypass; OR, oper-
ating room; DDAVP, desmopressin.
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Mreceiving rFVIIa and 5 patients undergoing reoperation
(P ¼ .41). The most common agent used was protamine
in the OR and ICU (Table 2).
Threshold for Reoperation or rFVIIa Use
Transfusion requirements with packed red blood cells
(PRBCs), fresh frozen plasma, platelets, and cryoprecipi-
tate intraoperatively and in the ICU before intervention
are shown in Figure 1, A and B. Eleven of 12 patients in
the rFVIIa group met chest tube output criteria. One patient
initially drained in excess of 3 mL $ kg1 $ h1, subsequently
stopped, and then trended back up to 2.2 mL $ kg1 $ h1.
This patient received rFVIIa and was included in our anal-
ysis. Seven of 12 patients in the reoperation group met chest
tube output criteria. Of those who did not, 3 were suspected
of having surgical bleeding at the discretion of the attending
surgeon, and 2 had evidence of hemothorax requiring evac-
uation and therefore were included in our analysis. No dif-
ferences were observed in coagulation values, body
temperature, pH, ionized calcium concentrations, or chestThe Journal of Thoracic and Cartube output before intervention (see Table E1). No differ-
ences were observed in intraoperative or preintervention
ICU blood use between groups. The average dose of rFVIIa
was 89.9  7.1 mg/kg per dose. No patient received more
than 1 dose.End Points for Efficacy
The rFVIIa group had a significant decrease in prothrom-
bin time and international normalized ratio values when
compared with the reoperation group (P<.0005). No sig-
nificant differences were observed with regard to other co-
agulation parameters or chest tube output (see Table E1).
There was a significant decrease in median blood product
use after intervention with rFVIIa (Table 3). However,
blood product use after intervention did not differ between
the 2 groups (Figure 1, C and D).
In the rFVIIa group hemostasis was achieved in 9 (75%)
of 12 patients. Chest tube output decreased from 5.0 to 1.4
mL $ kg1 $ h1 (P ¼ .002; Figure 2, A). Reoperation for
bleeding was required in 3 of 12 patients in this group (pa-
tients 2, 3, and 11). One patient (patient 11) bled from a right
coronary button after a valve-sparing aortic root and as-
cending and hemiarch replacement. In the other 2 cases
no obvious source of bleeding was identified.
In the reoperation group chest tube output decreased
from 3.6 to 1.3 mL $ kg1 $ h1 (P¼ .005; Figure 2,B). Eightdiovascular Surgery c Volume 141, Number 6 1471
FIGURE 1. (A) Comparison of transfusion requirements intraoperatively, (B) postoperatively but before intervention with recombinant activated factor VII
(rFVIIa) or reoperation, and (C) after intervention to 24 hours after the primary operation and (D) total blood product use in patients receiving rFVIIa or
reoperation for refractory coagulopathy in the intensive care unit. Numbers in parentheses represent multiple patients receiving the specified amount of
blood product. Box plots show the median, interquartile range, and minimum and maximum values. RBC, Red blood cells; Reop, reoperation; FFP, fresh
frozen plasma.
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Mpatients were found to have surgically correctable bleeding.
One patient bled from a vein graft, requiring reinstitution of
cardiopulmonary bypass for repair and a dose of rFVIIa toTABLE 3. Efficacy of intervention in patients who received rFVIIa or
reoperation for refractory coagulopathy in the intensive care unit
Preintervention,
median (range)
Postintervention,
median (range)
P
value
rFVIIa
RBC 5.0 (1–11) 2.0 (0–7) .022
FFP 6.0 (4–13) 0.0 (0–3) .002
Platelets 3.0 (2–6) 0.0 (0–2) .003
Cryoprecipitate 1.0 (0–1) 0.0 (0–1) .034
Reoperation
RBC 6.5 (2–17) 3.0 (0–10) .084
FFP 7.0 (3–19) 1.0 (0–7) .002
Platelets 3.0 (1–7) 1.5 (0–3) .019
Cryoprecipitate 1.0 (0–3) 0.0 (0–1) .018
rFVIIa, Recombinant activated factor FVII; RBC, red blood cells; FFP, fresh frozen
plasma.
1472 The Journal of Thoracic and Cardiovascular Surcontrol bleeding in the OR. In 4 patients no obvious bleed-
ing source was identified. One of these patients required
rFVIIa in the OR for hemostasis during reoperation after
aortic and mitral valve replacements and tricuspid repair.
Overall, 15 patients required reoperation for bleeding, re-
sulting in a calculated reoperation rate of 3.6% (15/421).
Total OR time was significantly lower in the rFVIIa
group (444 vs 599 minutes, P¼ .001). No significant differ-
ences in postoperative ventilator hours, ICU LOS, or LOS
calculated from the time of surgical intervention to dis-
charge were demonstrated (see Table E2).
End Points for Safety
In-hospital survival in both patient groups was 100%.
There were no significant differences in infection, thrombo-
sis, or renal failure (see Table E2). In the rFVIIa group there
was 1 pulmonary embolism and 1 episode of renal failure.
The pulmonary embolus was detected incidentally on a rou-
tine predischarge computed tomographic angiogram aftergery c June 2011
FIGURE 2. Chest tube output (A) before and after recombinant activated factor VII (rFVIIa) administration and (B) before and after reoperation for re-
fractory coagulopathy in the intensive care unit.
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Maortic surgery and caused no symptoms. The episode of re-
nal failure occurred in a patient with no preexisting renal
disease and resolved completely. Both of these patients
required reoperation for continued bleeding after rFVIIa
administration.
End Points for Economic Outcomes
No statistically significant differences were observed
with regard to hospital cost, charges, reimbursement, or
profit margin (see Table E3).
DISCUSSION
Excessive bleeding after cardiovascular surgical proce-
dures has been reported to occur in up to 20% of patients,
and surgical re-exploration might be required in 2% to
5% of patients.1-3,11,20 Complex cardiac procedures
present a 3-fold increased risk in rates of reoperation for
bleeding.2,3 Both surgical re-exploration and excessive
blood product replacement increase risk of infection, multi-
organ failure, thromboembolism, increased hospital and
ICU LOS, and mortality.1-7 Refractory blood loss despite
maximal standard therapy might be seen in up to 2% of
cases.12,17,20 In these cases other options to control
refractory hemorrhage are required.
rFVIIa was introduced in the United States in 1999. Its
mechanism of action is 3-fold. First, rFVIIa binds to ex-
posed tissue factor (TF) at the site of injury, activating factor
X and leading to thrombin formation and platelet activa-
tion.8,20 Second, rFVIIa binds to activated platelets
causing activation of factor X leading to TF-independent
thrombin generation.8 Finally, rFVIIa stabilizes clotting
by means of activation of the thrombin activation fibrinoly-
sis inhibitor.8
In 2004, we began using rFVIIa in the OR for refractory
bleeding after complex cardiovascular procedures. We
found that it effectively controlled nonsurgical bleeding,
reduced blood product use, and avoided reoperation for de-
layed sternal closure.15 In 2006, we began to use rFVIIa inThe Journal of Thoracic and Carthe ICU for refractory bleeding. Others have found that
this has reduced massive transfusion and reopera-
tion.9,10,12,14-16,18,19 However, this has not translated into
shorter LOS or lower morbidity or mortality. Concerns
regarding safety and cost continue to create controversy
about the use of rFVIIa in this setting.8,19,20
In the present comparison of reoperation with rFVIIa ad-
ministered in the ICU, we found both groups to be compa-
rable with regard to preoperative, intraoperative, and
postoperative characteristics. Both groups demonstrated
a similar significant decrease in chest tube output and blood
product use. Nine (75%) of 12 patients in the rFVIIa group
avoided reoperation. Similarly, reoperation was effective in
achieving hemostasis in 10 (83.3%) of 12 patients, with 2
requiring rFVIIa during reoperation. Patients receiving
rFVIIa had a significant decrease in the median OR time
compared with that seen in the reoperation group but no
significant differences in economic outcomes.
We found, as have others, that administration of rFVIIa in
the ICU produced a significant decrease in chest tube output
and blood product use,9,10,12,14-16,18,19 with similar results
observed with reoperation. Although no differences were
detected between the groups, this should be interpreted
with caution because patients suspected of having
a surgical source of bleeding underwent reoperation.
Similar to other studies, prothrombin time and interna-
tional normalized ratio were significantly less in patients
who received rFVIIa compared with values seen in patients
undergoing reoperation.9,12,14-16,18 In vitro rFVIIa exerts an
effect on the active ingredients in the test tube at laboratory
temperature and might not be representative of in vitro
effects.8 Thromboelastographic analysis might have predic-
tive value on potential response to rFVIIa but has been
found to poorly identify andmonitor changes in coagulation
after intervention.21 Adequacy of management of abnormal
coagulation parameters, hypothermia, acidosis, and hypo-
calcemia (predictive of poor response to rFVIIa) might
explain the wide range in response to rFVIIa, which isdiovascular Surgery c Volume 141, Number 6 1473
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Mreported to be between 60% and 100%.8-10,13-15,18,19,22 In
our study these parameters were similar and within
normal ranges in both groups before intervention.
In this high-risk cohort the incidence of postoperative
bleeding was 5.9%, and the reoperation rate was 3.6%,
which is consistent with published reports.1-3,7,20 Nine of
12 patients in the rFVIIa group avoided reoperation. In
the 3 re-explored patients, only 1 was found to have surgi-
cally correctable bleeding.
In our study rFVIIa was administered at an average single
dose of 89.9  7.1 mg/kg. Doses of rFVIIa used to control
postoperative hemorrhage in patients undergoing cardiac
surgery have ranged between 11 and 192 mg/kg per dose
in published reports.9-19 Romagnoli and colleagues9 con-
ducted a matched case–control analysis evaluating the use
of 1.2 mg of rFVIIa (11–21.5 mg/kg per dose), demonstrat-
ing a significant decrease in re-exploration and a trend to-
ward a decrease in mortality in the rFVIIa group. Masud
and associates18 observed a significant reduction in PRBC
use but no dose-response effect after rFVIIa administration
among all dosing quartiles greater than 30 mg/kg. Consen-
sus recommendations are for 1 to 2 doses of 35 to 70 mg/
kg to be given for bleeding that is refractory to standard
hemostatic therapies.23
Timing of rFVIIa dose relative to its efficacy is also of in-
terest. Prophylactic use of rFVIIa is not advocated because
the risks of rFVIIa might outweigh the benefits.20 More rel-
evant is the timing of rFVIIa administration as rescue ther-
apy for refractory bleeding. Karkouti and coworkers5
demonstrated that a transfusion requirement of 5 units of
PRBCs during the perioperative period increases the odds
for in-hospital mortality by 8-fold. They also evaluated
early (8 units of PRBCs) versus late (>8 units of PRBCs)
administration of rFVIIa and found a mortality rate of 7.6%
in the early treatment group compared with 27.1% in the
late group,11 a finding seen in other series.13 This supports
the early use of rFVIIa provided there are adequate amounts
of circulating factors.11,14,17 Our study reflects this
approach because a median of 5.0 (range, 1–11) units of
PRBCs was administered before rFVIIa.
Thromboembolic complications are of particular concern
with rFVIIa use.19 The TF–rFVIIa interaction occurs at
many levels, including the subendothelium, atherosclerotic
plaques, and ischemic myocardium.8,12,24 TF circulates
freely in patients with acute coronary syndromes and is
disseminated with the systemic inflammatory response to
cardiopulmonary bypass.8,24 As such, the interaction
between circulating TF and rFVIIa in cardiac surgical
patients might result in a hypercoagulable state.8,24 A
review of the US Food and Drug Administration’s
Adverse Event Reporting System database for rFVIIa
between 1999 and 2004 suggested there were increased
thromboembolic events in patients treated for unlabeled
conditions, with 1 in 50 experiencing a thromboembolic1474 The Journal of Thoracic and Cardiovascular Surcomplication and 1 in 200 patients dying.25 Thrombosis
rates reported in case reports and case–control series in
patients undergoing cardiac surgery range from 0% to
25%.9,10,12,14-16,18,19 The use of rFVIIa has been
associated with increased renal failure.12,15 A
comprehensive Canadian review demonstrated a major
morbidity rate of 44% in patients receiving off-label use
of rFVIIa in cardiac surgery, but this did not differ from
a separate reference cohort of cardiac surgical patients
who did not receive rFVIIa.17 A recent meta-analysis in-
cluding 5 studies and a randomized placebo-controlled trial
both evaluated rFVIIa use for refractory bleeding in patients
undergoing cardiac surgery and showed an increased but
not statistically significant incidence of stroke.19,22 Our
study demonstrated a very low incidence of adverse
effects, with no significant differences in the incidence of
infection, thrombosis, or renal failure between the 2
groups. Two adverse events (1 pulmonary embolism and 1
episode of renal failure) were observed in the rFVIIa
group. However, both patients also required reoperation
for continued bleeding after rFVIIa administration. A
well-designed randomized controlled trial is needed to ade-
quately determine the risk of rFVIIa administration in this
patient population.
With regard to the potential clinical benefits of rFVIIa-
mediated reduction in blood use, Gelsomino and
colleagues16 demonstrated a significant reduction in both
mechanical ventilation time and ICU LOS with use of
low-dose rFVIIa. However, Tritapepe and associates14 dem-
onstrated no difference in ICU or hospital LOS in 23 pa-
tients with refractory bleeding undergoing acute aortic
dissection surgery with deep hypothermic circulatory arrest
compared with that seen in 23 matched control subjects. No
significant effect on survival has been observed in patients
receiving rFVIIa for refractory bleeding after cardiac sur-
gery.9,14,16,19,22 The only published randomized placebo-
controlled trial addressing rFVIIa use in this population
did not address any of the above end points; however, a non-
statistically significant doubling of mortality was ob-
served.19 It is possible that the lack of statistical
significance might have been the result of a type II error in-
volving inadequate enrolment to detect this difference.19
Our study demonstrated a significant difference in median
OR time in the rFVIIa group that was attributable to the
low incidence of reoperation in this group. Median ventila-
tor time, ICU LOS, and hospital LOS were not significantly
different, and in-hospital survival for both groups was
100%. This suggests that the efficacy of rFVIIa use in
this setting might be equivalent to that of reoperation in se-
lect patients. Additional adequately powered studies will be
required to evaluate this scenario and further address safety
concerns.
Excessive postoperative bleeding after cardiovascular
surgical procedures places a high demand on hospitalgery c June 2011
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Mresources, leading to increased hospital costs.6,7 Strategies
that can effectively reduce the incidence or severity of
this complication might potentially reduce morbidity,
mortality, resource use, and cost.6,7 When comparing
rFVIIa administration in the ICU with reoperation for
refractory bleeding after cardiovascular surgery, we found
the groups to be comparable, with no significant
differences in hospital cost, charges, reimbursement, or
profit. The reduction in OR time and resource use
observed in the rFVIIa group did not appear to translate
into a significant decrease in hospital costs. A study
performed by Christensen and coworkers7 comparing pa-
tients with and without excessive postoperative hemorrhage
after cardiac surgery demonstrated that ICU stay dominated
overall cost (51%), followed by the cost of manpower re-
quirements (28%) and LOS in the general ward (10%),
with blood transfusion and cost of reoperation accounting
for only 4% and 3% of the cost, respectively. This might
explain the lack of effect that OR time had on cost in our
study. However, this might allow the opportunity to use
these resources in other areas to generate additional
revenue.
Several limitations need to be considered when interpret-
ing our results. Our study is a retrospective nonrandomized
trial with a limited sample size and therefore underpowered.
Our findings should therefore be viewed as associative
rather than causative. Eight of the 12 patients in the reoper-
ation group were found to have a surgically correctable
cause of bleeding, suggesting both that clinical judgment
is important to the success of rFVIIa treatment and an inher-
ent selection bias in this study. In addition, it is possible that
nonsignificant differences between the groups with regard
to the distribution of various patients’ demographics and
risk variables (Table 1) might have affected bleeding out-
comes in this analysis. All patients in the reoperation group
were identified before July 2006, and all patients meeting
bleeding criteria after July 2006 were given rFVIIa. This in-
troduces a time-related bias because no patients in the reop-
eration group had the option of receiving rFVIIa.We did not
follow any long-term outcome data for either group in this
study. Hospital cost, charge, and reimbursement data might
be fairly unique to our institution and might not be widely
applicable. We attempted to adjust cost data for inflation
and increase in hospital capital expenditures over the study
timeframe; however, a more concurrent treatment and
control group is preferred.
In conclusion, rFVIIa administration in the ICU appears
to be comparable with reoperation with respect to efficacy
in patients with refractory bleeding after complex cardio-
vascular surgery. Reduction in reoperation and OR time
and cost of rFVIIa did not correlate with any difference in
overall cost. In properly selected patients rFVIIa can be
used as an alternative to reoperation for bleeding after
cardiovascular surgery. Future prospective, randomizedThe Journal of Thoracic and Carcontrolled trials are needed to clearly assess the safety of
off-label use of rFVIIa in this setting.References
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Dr Arvind K. Agnihorti (Boston, Mass). Thank you, Dr Cohn,
and thank you, Dr Toole, for this interesting study about a poten-
tially useful adjunct in cardiac surgery. I have 2 comments and
then a few questions.
As I read your article, I thought about bleeding in postoperative
cardiac surgery and how we deal with a continuum from coagulop-
athy to surgical sources of bleeding; the 2 obviously are interre-
lated, and one can beget the other. In this article, which is
retrospective, your surgeons tried to determine whether the pa-
tients had a coagulopathy or a surgical source of bleeding and
then proceeded to either reoperate on them or potentially to use
this drug. Therefore these are really 2 different populations of pa-
tients, and I think that limits the way that we can approach a com-
parison, as it was done in your study.
The second thing I wanted to point out was that the use of this
drug did not appear to improve the outcomes for your patients.
Therefore another way to look at this study is that reoperation in
the absence of factor VII is also a safe and efficacious way to
deal with postoperative hemorrhage, and I was a bit surprised
that the use of this drug did not show any apparent reduction in
cost.
I have a couple of questions. The first has to do with safety. In
the group of patients who received factor VII, 25% (n ¼ 3) ulti-
mately required an operation. In that group 2 of 3 had a complica-
tion that might be attributed to stroke: 1 had a pulmonary
embolism, and 1 had renal failure. I want you to comment on
the possible risk of application of this drug in a patient who has sur-
gical bleeding and is being treated for coagulopathy.
Dr Toole. Thank you very much for those comments. I think
that is a very important point and one that we have gone to great
lengths to minimize: the administration of a thrombogenic drug
to a patient with a relatively normal coagulation system. As you
have pointed out, there seems to be a continuum from surgical
bleeding to coagulopathy. The definition of surgical bleeding at
our institution might be changing, as referenced by the change
in our practices from reoperation to administering factor VII to al-
most everybody. I think that the reason we only found 1 patient
with surgical bleeding in the factor VII group is that a lot of things
that we would consider surgical bleeding might have stopped with
factor VII. Examples would be sternal wires and small mediastinal
vessels.
Your concerns about safety are appropriate. Certainly we did
not have the statistical power to make any comments about that.
I think it is a point worth making that designing a study to detect1476 The Journal of Thoracic and Cardiovascular Surdifferences in safety is extremely difficult. Gill, in the Journal of
Thoracic and Cardiovascular Surgery in 2009, consented more
than 2600 patients and only dosed about 170. The amount of
work to consent patients and then randomize them into a study
is enormous. In our study only 5% of high-risk patients had signif-
icant postoperative bleeding. This is an inherent problem with pro-
spectively studying these patients. Even with their cohort of 170
patients, they believed that they were underpowered to make any
comment on statistical significance as far as safety.
Dr Agnihotri. Did you look at postoperative creatinine values
in your patients? I noted that the renal failure rate was not statisti-
cally different, but did you see any increase in the treatment group
in terms of their peak creatinine values?
Dr Toole. We did not see that.
Dr Agnihotri. You chose a dose of about 90 mg/kg as a single
dose. Others have used smaller doses and given multiple smaller
doses. Do you have experience with that, and can you comment
on why you chose that dose?
Dr Toole. We began using the 90 mg/kg dose because that is the
recommended dose set forth by the manufacturer for the treatment
of patients with hemophilia. More recent studies suggest that ear-
lier dosing and smaller doses, with ranges between 30 and 70 mg/
kg, might be effective. To some extent, we have adopted that
strategy.
Dr Agnihotri. Thank you very much.
Dr SimonMoten (Melbourne, Australia). At our institution, we
have a large experience with the use of recombinant factor VII and
are currently involved in a randomized controlled trial for its use in
the operative setting. My comment and question is that in the post-
operative setting, if people are bleeding, the important factor is the
timing at the time of intervention when you realize that patients do
require further intervention to correct their bleeding, either return
to the operating theater or other measures. In your study did you
find that there was any difference in the timing between the 2
groups that might have led to a difference in their outcomes? Cer-
tainly I believe that earlier intervention in this group is important
for reducing the overall complication rate.
Dr Toole. I agree with you wholeheartedly. We did not specif-
ically look at timing. The bleeding criteria that we used measured
chest tube output for the 2 hours before intervention. Once a patient
reached the criteria for either reoperation or dosing with factor VII,
no more than 2 hours had passed. However, we did have several
patients, especially in the earlier reoperation group, who had mod-
erate chest tube output not meeting the bleeding criteria overnight
but that increased, and these patients underwent reoperation on the
following day.
Dr Domenico Paparella (Bari, Italy). It is hard to define coa-
gulopathy. As you know, there are several reasons why we can
have coagulopathy after cardiac surgery. It can be platelet dysfunc-
tion, hyperfibrinolysis, or coagulation factor consumption. Did
you try to analyze the reason for coagulopathy by using any
point-of-care test?
Dr Toole. No, we did not.
Dr Paparella. Okay. I think that makes the choice of adminis-
tering recombinant factor VII to all bleeding patients not very bal-
anced because you do not know why your patients are bleeding.
Dr Toole. Our criteria for giving factor VII required that coag-
ulation test results be relatively normal, bywhich Imean a a plateletgery c June 2011
Uber et al Perioperative Managementcount of greater than 100,000, an international normalized ratio of
less than 1.5, a complete reversal of the partial thromboplastin
time, and a fibrinogen level of greater than 200, but we did not nec-
essarily use a point-of-care test to adjust those. I think what you are
referring to is a thromboelastogram, which we did not routinely
use on all bleeding patients postoperatively.
DrG.Hossein Almassi (Milwaukee, Wis). Did you have in your
group of factor VII recipients any patients with diseases that would
predispose to bleeding, such as myelomonocytic leukemia, in
which no matter what you do they bleed, or any other type of
malignancy that would predispose them to it? Do you have any
experience in that regard?
Dr Toole. We did not have any patients with any of those con-
ditions or any personal or family history of bleeding disorders.
Dr A. W. Atkinson (Raleigh, NC). The earlier comment that
you do not have any quantitative defect in your clinical assessment
of why the patient is bleeding and yet he or she is bleeding was in-
teresting, and it appears that when you give some patients factor
VII, they stop bleeding. It just might be that we are not doing
the right test yet. Maybe we ought to get a quantitative level for
factor VII or some other proton, partial thromboplastin time,
something we are not doing right so we know when to give this
drug. It appears that there is a relative deficiency of this part ofThe Journal of Thoracic and Carthe cascade, and we just have not learned to test for it yet. How
about that?
Dr Toole. I agree with you. It is difficult to assess exactly what
the deficiency is unless there is a specific abnormality that shows
up in the coagulation laboratory studies. We try very hard to cor-
rect all of those: first so we do not have to give the patient factor
VII if they do not need it, but second because once the factor
VII is given, it relies on all of those downstream components of
the clotting cascade to get the job done. Giving a patient with
coagulation abnormalities factor VII is not likely to help them.
Dr Atkinson. There was not anybody who was still bleeding
after you fixed the surgical problem if it existed and you gave
them factor VII, right?
Dr Toole. That is correct.
Dr Lawrence H. Cohn (Boston, Mass). I have one question.
You said it was a very expensive drug. Can you give us a sense
of the sort of average cost of the use of this recombinant factor
in these patients?
Dr Toole. Factor VII itself costs about $1000 a milligram. We
gave it in a 90 mg/kg dose. Not everybody uses that dose. Unfortu-
nately, our average patient in South Carolina weighs between 90
and 100 kg, and therefore our average cost of factor VII is about
$9,000 per dose.diovascular Surgery c Volume 141, Number 6 1477
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TABLE E1. Comparison of coagulation parameters in patients before and after administration of rFVIIa or reoperation for refractory
coagulopathy in the intensive care unit
rFVIIa (n ¼ 12) Reoperation (n ¼ 12) P value
Preintervention, median (range)
aPTT (s) 40.6 (33.0–56.5) 40.8 (36.8–67.6) .551
PT (s) 17.5 (10.3–21.9) 17.5 (17.1–27.5) .198
INR 1.37 (0.68–1.82) 1.38 (1.31–2.49) .219
Fibrinogen (mg/dL) 281 (163–381) 282 (122–351) .606
Platelets (1000/mm3) 134 (69–182) 111 (48–213) .266
Body temperature (C) 35.7 (34.9–37.6) 35.6 (34.1–36.7) .799
pH 7.40 (7.29–7.46) 7.41 (7.23–7.47) 1.000
Ionized calcium (mmol/L) 1.11 (0.67–1.50) 1.15 (0.80–1.35) .932
Chest tube output (mL $ kg1 $ h1) 5.0 (1.6–10.2) 3.6 (0.4–13.0) .319
Postintervention, median (range)
aPTT (s) 31.8 (30.5–39.2) 34.8 (30.0–39.1) .175
PT (s) 11.7 (10.8–13.9) 16.4 (12.9–20.3) <.0005
INR 0.82 (0.73–1.01) 1.25 (0.90–1.70) <.0005
Fibrinogen (mg/dL) 296 (199–398) 290 (199–370) .902
Platelets (1000/mm3) 112 (97–197) 129 (90–190) .319
Body temperature (C) 37.3 (36.0–37.9) 37.4 (36.7–38.6) .410
pH 7.42 (7.30–7.54) 7.40 (7.36–7.47) .932
Ionized calcium (mmol/L) 1.20 (1.0–1.4) 1.20 (0.9–1.5) .512
Chest tube output (mL $ kg1 $ h1) 1.4 (0.36–4.00) 1.3 (0.6–2.7) .266
rFVIIa, Recombinant activated factor VII; aPTT, activated partial thromboplastin time; PT, prothrombin time; INR, international normalized ratio.
TABLE E2. Associated outcomes in patients who received rFVIIa or
reoperation for refractory coagulopathy in the intensive care unit
Outcome
rFVIIa
(n ¼ 12)
Reoperation
(n ¼ 12)
P
value
Survival to discharge 12 (100%) 12 (100%)
Permanent stroke 0 0
Mediastinitis 0 0
Acute limb ischemia 0 0
Perioperative MI 0 0
Pneumonia 0 0
Pulmonary embolism 1 (8%) 0 1.000
Renal failure 1 (8%) 0 1.000
Dialysis required 0 0
Total OR time (min)
Median 444 599 .001
Range 359–698 495–754
Postoperative ventilator time (h)
Median 17 24 .128
Range 10–117 12–206
Intensive care unit stay (h)
Median 89 117 .671
Range 41–268 24–301
LOS surgery to discharge (d)
Median 9.0 8.5 .843
Range 4–18 4–23
rFVIIa, Recombinant activated factor VII; MI, myocardial infarction; OR, operating
room; LOS, length of stay.
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TABLE E3. Comparison of economic data in patients who received rFVIIa or underwent reoperation for refractory coagulopathy in the intensive
care unit
Normalized values rFVIIa (n ¼ 12) Reoperation (n ¼ 12) P value
Hospital cost adjusted for inflation
Median $58,976 $62,433 .755
Range $40,689 to $173,381 $35,253 to $139,703
Hospital cost adjusted for capital expenditure
Median $60,418 $78,041 .220
Range $43,944 to $187,252 $44,066 to $164,849
Hospital charges
Median $137,462 $134,156 .410
Range $98,816 to $256,503 $75,931 to $235,922
Reimbursement
Median $51,132 $54,876 .514
Range $0 to $164,675 $28,489 to $177,392
Profit margin adjusted for inflation
Median $16,631 $3,885 .128
Range $57,893 to $22,279 $43,380 to $74,801
Profit margin adjusted for capital expenditure
Median $21,419 $16,885 .684
Range $57,893 to $11,598 $69,188 to $56,335
rFVIIa, Recombinant activated factor VII.
Uber et al Perioperative Management
The Journal of Thoracic and Cardiovascular Surgery c Volume 141, Number 6 1477.e2
P
M
